semaglutide for nafld 🎉Exciting news that is now FDA approved MASH (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% Semaglutide Shows Promise for Fatty

Cosmetic-grade GHK-Cu, labelled under the INCI name Copper Tripeptide-1, is supplied for incorporation into finished topical cosmetic products under the Cosmetic Regulations, with formulation-grade documentation

Results are inconsistent and slow 1

Recovery of the hepatic GSH was delayed in the Aldh2*2 KI homozygous mice compared with the WT mice

PubMed Spth-Schwalbe E, Schller T, Kern W, et al

The most significant clinical data on retatrutide to date come from a Phase 2 randomised controlled trial published in the New England Journal of Medicine (2023), which evaluated the drug across multiple doses in adults with obesity

Takahashi, Y., Ogra, Y